Results 11 to 20 of about 7,028 (198)

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis [PDF]

Journal of Dermatological Treatment
Background Janus kinase 1 inhibitor upadacitinib is therapeutically effective for atopic dermatitis (AD). However, predictive factors for high responders to upadacitinib have not been established in real-world clinical practice.Objectives To identify ...
Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda   +5 more
doaj   +2 more sources

Trial of upadacitinib and adalimumab for psoriatic arthritis [PDF]

, 2022
S.1227-1239Background The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor a inhibitor, in patients who have an inadequate ...
McInnes, I.B., Pangan, A.L., PachecoTena, C., Liu, Y., Jeka, S., Behrens, F., Anderson, J.K., Kishimoto, M., Magrey, M., Merola, J.F., Chen, L., Zueger, P., Wang, X., Liu, J.   +13 more
core   +4 more sources

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program [PDF]

, 2021
Treating to a target of clinical remission or low disease activity is an important principle for managing rheumatoid arthritis (RA). Despite the availability of biologic disease-modifying antirheumatic drugs (bDMARDs), a substantial proportion of ...
Mysler, E, Cohen, Stanley, Enejosa, JV, Nash, P, Tanaka, Y, Mysler, Eduardo, Da Silva-Tillmann, B, Cohen, S, Shaw, Tim, Da Silva-Tillmann, Barbara, Burmester, G, Tanaka, Yoshiya, Ferguson, Ryan, Nash, Peter, Rigby, W, Liu, J, Rigby, William, Burmester, Gerd, Conaghan, PG, Ferguson, R, Liu, John, Enejosa, Jeffrey V, Conaghan, Philip G, Shaw, T   +23 more
core   +1 more source

Upadacitinib in refractory ulcerative colitis patients with high thromboembolic risk: two case reports [PDF]

Frontiers in Immunology
Upadacitinib is a novel selective Janus kinase (JAK) inhibitor approved for adults with ulcerative colitis (UC). While caution is advised when considering upadacitinib as a treatment option for patients with an increased risk of thrombosis.
Rui Mo, Shuxia Yu, Hongwei Xu, Jinghua Hao   +3 more
doaj   +2 more sources

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis [PDF]

, 2021
International audienceObjective: To assess the efficacy and safety of upadacitinib, an oral Janus kinase inhibitor, as monotherapy or in combination with non-biologic DMARDs (nbDMARDs) in patients with PsA.Methods: Pooled data were analysed from patients
Kato, Koji, Ruderman, Eric, M, Ruderman, Eric M, Gossec, Laure, Lesser, Elizabeth, Nash, Peter, Ritchlin, Christopher, Mccaskill, Reva, McDearmon-Blondell, Erin L, Marchesoni, Antonio, Feng, Dai, Anderson, Jaclyn K, Anderson, Jaclyn, K, Richette, Pascal, Mcdearmon-Blondell, Erin, L   +14 more
core   +1 more source

Upadacitinib tartrate in rheumatoid arthritis [PDF]

, 2020
In rheumatoid arthritis (RA) there is an unmet therapeutic need, as a substantial proportion of patients does not achieve low disease activity or remission despite the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or ...
Bogdanos, Dimitrios P., Sakkas, Lazaros, Stamatis, P., Bogdanos, D.P., Stamatis, Pavlos, Sakkas, L.I.   +5 more
core   +3 more sources

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials [PDF]

, 2021
Introduction: This integrated analysis describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, at 15 and 30 mg once daily for up to 3 years of exposure in patients with active psoriatic arthritis (PsA) who had a prior inadequate ...
Rubbert-Roth, Andrea, Lippe, Ralph, Lertratanakul, Apinya, Ruderman, Eric M, Blanco, Ricardo, Mccaskill, Reva M, Lesser, Elizabeth, Nash, Peter, Burmester, Gerd R, Azevedo, Valderilio F, Winthrop, Kevin, Liu, John, Salvarani, Carlo, Goupille, Philippe   +13 more
core   +1 more source

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis [PDF]

, 2023
Objectives To provide an integrated analysis of major adverse cardiovascular events (MACEs) and events of venous thromboembolism (VTE) and associated risk factors across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS)
Mysler, E, Christina Charles-Schoeman, Nasser Khan, Choy, Ernest, Curtis, Jeffrey R., Nash, P, Khan, N, Mysler, Eduardo, Iain B McInnes, Ralph Lippe, Lippe, Ralph, Lippe, R, Eduardo Mysler, Yamaoka, Kunihiro, Choy, E, Jessica Suboticki, Curtis, Jeffrey R, Ernest Choy, Curtis, JR, Shmagel, Anna K., McInnes, Iain B., Suboticki, J, Peter Nash, Shmagel, Anna K, Hannah Palac, Yamaoka, K, Kunihiro Yamaoka, Jeffrey R Curtis, Charles-Schoeman, C, McInnes, IB, Charles-Schoeman, Christina, Nash, Peter, Khan, Nasser, Shmagel, AK, Suboticki, Jessica, McInnes, Iain B, Anna K Shmagel, Palac, Hannah, Palac, H   +38 more
core   +1 more source

Upadacitinib [PDF]

pharma-kritik, 2020
Ein weiterer Januskinase-Hemmer, der bei der rheumatoiden Arthritis eingesetzt werden kann. Bisher vorliegende Vergleiche mit Placebo, Methotrexat und Adalimumab lassen eine gute Wirksamkeit der neuen Substanz annehmen; es sind aber erst wenig Langzeitdaten verfügbar.
openaire   +2 more sources

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease [PDF]

, 2023
peer reviewedBACKGROUND: Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is under investigation for the treatment of Crohn's disease.
Julian Panés, Boland, Brigid S, Liu, Jianzhong, Panaccione, Remo, Jianzhong Liu, Geert D’Haens, D'Haens, Geert, Mohamed-Eslam F. Mohamed, Reinisch, Walter, Chen, Minhu, Phillips, Charles, Tian Feng, Minhu Chen, Charles Phillips, Walter Reinisch, Dubcenco, Elena, Brigid S. Boland, Mohamed, Mohamed-Eslam F, Edouard Louis, Geng, Ziqian, Jakob Begun, Loftus, Edward V Jr, Jean-Frederic Colombel, Elena Dubcenco, Ana P. Lacerda, Edward V. Loftus, Laurent Peyrin-Biroulet, Remo Panaccione, Ziqian Geng, Louis, Edouard, Hiroshi Nakase, Panés, Julian, Lacerda, Ana P, Feng, Tian, Nakase, Hiroshi, Colombel, Jean-Frederic, Peyrin-Biroulet, Laurent, Begun, Jakob   +37 more
core   +1 more source